US 12,465,634 B2
Use of trimanganese tetraoxide particles in preparation of vaccine adjuvant
Yaling Wang, Guangzhou (CN); Chunying Chen, Guangzhou (CN); and Yuliang Zhao, Guangzhou (CN)
Assigned to Guangzhou Realbenefitspot Pharmaceutical Co., Ltd., Guangzhou (CN)
Filed by Guangzhou Realbenefitspot Pharmaceutical Co., Ltd., Guangzhou (CN)
Filed on Jul. 3, 2024, as Appl. No. 18/763,977.
Application 18/763,977 is a continuation of application No. PCT/CN2023/079905, filed on Mar. 6, 2023.
Claims priority of application No. 202210018495 (CN), filed on Jan. 7, 2022.
Prior Publication US 2025/0057947 A1, Feb. 20, 2025
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61K 39/002 (2006.01); A61K 39/005 (2006.01); A61K 39/008 (2006.01); A61K 39/015 (2006.01); A61K 39/145 (2006.01); A61K 39/215 (2006.01); A61P 37/04 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 39/0003 (2013.01); A61K 39/002 (2013.01); A61K 39/005 (2013.01); A61K 39/008 (2013.01); A61K 39/015 (2013.01); A61K 39/145 (2013.01); A61K 39/215 (2013.01); A61P 37/04 (2018.01); A61K 2039/55505 (2013.01); A61K 2039/55561 (2013.01)] 21 Claims
OG exemplary drawing
 
1. An adjuvant composition comprising an adjuvant particle comprising:
(a) a trimanganese tetraoxide particle,
(b) a single nucleotide or a single-stranded nucleotide, and
(c) an excipient, wherein the excipient comprises a protein, a polypeptide, a polymer, a nucleic acid, or a polysaccharide, wherein the excipient and the single nucleotide or the single-stranded nucleotide form a covalent bond, and wherein the size of the adjuvant particle is about 5 nm to about 3000 nm, wherein the covalent bond is based on a chemically selective covalent modification group pair carried by the excipient and the single nucleotide or the single-stranded nucleotide.